Telithromycin-induced digoxin toxicity and electrocardiographic changes

Pharmacotherapy

Volumn 26, Issue 6 I, 2006, Pages 872-876

  Nenciu, Laura M ^a   Laberge, Patrice ^a   Thirion, Daniel J G ^a,b  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adverse effect; Digoxin; Drug interaction; Macrolides; Telithromycin

Indexed keywords

BISOPROLOL; BUDESONIDE; CREATINE KINASE MB; DIGOXIN; FOSINOPRIL; GLYCOPROTEIN P; HYDROCHLOROTHIAZIDE; MAGNESIUM SULFATE; OMEPRAZOLE; PAROXETINE; PROGESTERONE; TELITHROMYCIN; TERBUTALINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CASE REPORT; DIGITALIS INTOXICATION; DIGOXIN BLOOD LEVEL; DRUG TRANSPORT; ELECTROCARDIOGRAM; FEMALE; HEART PALPITATION; HUMAN; HYPOMAGNESEMIA; MALAISE; ORTHOSTATIC HYPOTENSION; SYNCOPE; TACHYCARDIA;

ACUTE DISEASE; BRONCHITIS; DIGOXIN; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; KETOLIDES; MIDDLE AGED;

EID: 33744487647     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.6.872     Document Type: Article

References (28)

1. Prybys KM. Deadly drug interactions in emergency medicine. Emerg Med Clin North Am 2004;22:845-63.
2. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8.
3. Gaddis GM, Holt TR, Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med 2002;9:1162-7.
4. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
5. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphism in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75(1):13-33.
6. Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72:209-19.
7. Tanaka H, Matsumoto K, Ueno K, et al. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother 2003;37:178-81.
8. Hirata S, Izumi S, Furukubo T, et al. Interactions between clarithromycin and digoxin in patients with end-stage renal disease. Int J Clin Pharmacol Ther 2005;43:30-6.
9. Zapater P, Reus S, Tello A, Torrus D, Perez-Mateo M, Horga JF. A prospective study of the clarithromycin-digoxin interaction in elderly patients. J Antimicrob Chemother 2002;50:601-6.
10. Xu H, Rashkow A. Clarithromycin-induced digoxin toxicity: a case report and a review of the literature. Conn Med 2001;65(9):527-9.
11. Gooderham MJ, Bolli P, Fernandez PG. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. Ann Pharmacother 1999;33:796-9.
12. Laberge P, Martineau P. Clarithromycin-induced digoxin intoxication. Ann Pharmacother 1997;31:999-1002.
13. Guerriero SE, Ehrenpreis E, Gallagher KL. Two cases of clarithromycin-induced digoxin toxicity. Pharmacotherapy 1997;17:1035-7.
14. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23(2):106-31.
15. Morton MR, Cooper JW. Erythromycin-induced digoxin toxicity. Drug Intell Clin Pharm 1989;23:668-70.
16. Shain CS, Amsden GW. Telithromycin: the first of the ketolides. Ann Pharmacother 2002;36:452-64.
17. Aventis Pharma Inc. Ketec (telithromycin) product monograph. Laval, Quebec, Canada; 2005.
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
19. Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. Br Heart J 1976;38(2):167-72.
20. Tsutsumi K, Kotegawa T, Kuranari M, et al. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. J Clin Pharmacol 2002;42:1159-64.
21. Rengelshausen J, Goggelmann C, Burhenne J, et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 2003;56:32-8.
22. Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 1991;32:569-72.
23. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004;76:73-84.
24. Leahey EB Jr, Bigger JT Jr, Butler VP Jr, et al. Quinidine-digoxin interaction: time course and pharmacokinetics. Am J Cardiol 1981;48:1141-6.
25. Schenck-Gustafsson K, Dahlqvist R. Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br J Clin Pharmacol 1981;11:181-6.
26. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263-86.
27. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration adverse event reporting system. Clin Infect Dis 2002;35:197-200.
28. Milberg P, Eckardt L, Brans HJ, et al. Divergera proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early after depolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303:218-25.